Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

Thomas T. Deleon, Daniel Ahn, James M. Bogenberger, Panagiotis Z Anastasiadis, Mansi Arora, Ramesk K Ramanathan, Bashar A. Aqel, George Vasmatzis, Mark Truty, Rahmi Oklu, Tanios Bekaii-Saab, Mitesh J Borad

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.

Original languageEnglish (US)
Pages (from-to)553-566
Number of pages14
JournalFuture Oncology
Volume14
Issue number6
DOIs
StatePublished - Mar 1 2018

Fingerprint

Biliary Tract Neoplasms
Hepatocellular Carcinoma
Neoplasms
Biomarkers
Therapeutics
Investigational Therapies
Cholangiocarcinoma
Second Primary Neoplasms
Tumor Burden

Keywords

  • biomarkers
  • cholangiocarcinoma
  • gallbladder cancer
  • hepatocellular cancer
  • immunotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. / Deleon, Thomas T.; Ahn, Daniel; Bogenberger, James M.; Anastasiadis, Panagiotis Z; Arora, Mansi; Ramanathan, Ramesk K; Aqel, Bashar A.; Vasmatzis, George; Truty, Mark; Oklu, Rahmi; Bekaii-Saab, Tanios; Borad, Mitesh J.

In: Future Oncology, Vol. 14, No. 6, 01.03.2018, p. 553-566.

Research output: Contribution to journalReview article

@article{2f75b3dbe7eb4d43880bfc5df0181ef6,
title = "Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma",
abstract = "Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.",
keywords = "biomarkers, cholangiocarcinoma, gallbladder cancer, hepatocellular cancer, immunotherapy, targeted therapy",
author = "Deleon, {Thomas T.} and Daniel Ahn and Bogenberger, {James M.} and Anastasiadis, {Panagiotis Z} and Mansi Arora and Ramanathan, {Ramesk K} and Aqel, {Bashar A.} and George Vasmatzis and Mark Truty and Rahmi Oklu and Tanios Bekaii-Saab and Borad, {Mitesh J}",
year = "2018",
month = "3",
day = "1",
doi = "10.2217/fon-2017-0451",
language = "English (US)",
volume = "14",
pages = "553--566",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

AU - Deleon, Thomas T.

AU - Ahn, Daniel

AU - Bogenberger, James M.

AU - Anastasiadis, Panagiotis Z

AU - Arora, Mansi

AU - Ramanathan, Ramesk K

AU - Aqel, Bashar A.

AU - Vasmatzis, George

AU - Truty, Mark

AU - Oklu, Rahmi

AU - Bekaii-Saab, Tanios

AU - Borad, Mitesh J

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.

AB - Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.

KW - biomarkers

KW - cholangiocarcinoma

KW - gallbladder cancer

KW - hepatocellular cancer

KW - immunotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85042850798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042850798&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0451

DO - 10.2217/fon-2017-0451

M3 - Review article

VL - 14

SP - 553

EP - 566

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -